Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Moodys
Merck
Medtronic
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

LASTACAFT Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Lastacaft patents expire, and what generic alternatives are available?

Lastacaft is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-one patent family members in twenty-eight countries.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcaftadine profile page.

Drug patent expirations by year for LASTACAFT
Drug Prices for LASTACAFT

See drug prices for LASTACAFT

Generic Entry Opportunity Date for LASTACAFT
Generic Entry Date for LASTACAFT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LASTACAFT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganN/A
ORA, Inc.Phase 4
Starx Research Center, LLCPhase 4

See all LASTACAFT clinical trials

Recent Litigation for LASTACAFT

Identify potential future generic entrants

District Court Litigation
Case NameDate
Allergan, Inc. v. Aurobindo Pharma Ltd.2017-09-08
Allergan, Inc. v. Somerset Therapeutics, LLC2016-05-26

See all LASTACAFT litigation

Pharmacology for LASTACAFT
Synonyms for LASTACAFT
(Unlabelled)Alcaftadine-13C-D3
11-(1-methyl-4-piperidylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,3-b][3]benzazepine-3-carbaldehyde
11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carbaldehyde
147084-10-4
2-(1-methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0;{3,7}]tetradeca-1(14),3,5,10,12-pentaene-6-carbaldehyde
5H-Imidazo(2,1-b)(3)benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1-methyl-4- piperidinylidene)-
5H-Imidazo[2,1-b][3]benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-
5H-Imidazo[2,1-b][3]benzazepine-3-carboxaldehyde,6,11-dihydro-11-(1-methyl-4-piperidinylidene)-
7Z8O94ECSX
AC-28019
AKOS025402002
alcaftadina
Alcaftadine
Alcaftadine (JAN/USAN/INN)
Alcaftadine [USAN:INN]
Alcaftadine, >=98% (HPLC)
alcaftadinum
AM84429
AN-022
AOB6728
API0007478
BCP04261
BCP0726000082
BCP9000269
CHEBI:71023
CHEMBL1201747
CS-2842
D06552
DB06766
DTXSID80598455
FT-0661472
GTPL7587
HY-17039
Lastacaft (TN)
MolPort-023-219-144
R 89674
R-89674
R89674
s4625
SCHEMBL1602418
UNII-7Z8O94ECSX
Vilasta
X6443
ZINC11726211
Paragraph IV (Patent) Challenges for LASTACAFT
Tradename Dosage Ingredient NDA Submissiondate
LASTACAFT SOLUTION/DROPS;OPHTHALMIC alcaftadine 022134 2014-07-30

US Patents and Regulatory Information for LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKinsey
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.